Bayer recently made a significant stride in the realm of biotech innovation with the launch of Bayer Co.Lab AdVenture in China. This new platform, an extension of Bayer Co.Lab’s global life sciences incubator network, serves as a vital link to venture capital partners worldwide. By connecting high-potential biotech startups with leading venture capital firms, Bayer Co.Lab AdVenture aims to expedite access to global financing and investment networks, ultimately propelling early-stage ideas towards becoming impactful global solutions. The unveiling of this platform coincided with the first anniversary of Bayer Co.Lab Shanghai, where two additional Chinese biotech startups were welcomed into the fold, marking a pivotal moment in Bayer’s open innovation strategy.
Juergen Eckhardt, M.D., head of business development and licensing at Bayer’s Pharmaceuticals Division, emphasized the importance of collaboration in propelling pharmaceutical innovation forward. He highlighted that through initiatives like Bayer Co.Lab AdVenture, the company is partnering with prominent venture capital firms to empower biotech start-ups by facilitating access to global financing and investment networks, thereby accelerating their growth trajectories. This collaborative approach is integral to Bayer’s commitment to deepening connections with innovators and partners to drive transformative innovations that address global health challenges and enhance outcomes for patients worldwide.
The inaugural partners of Bayer Co.Lab AdVenture, including Shanghai Industrial Investment Capital (SIIC), Legend Capital, IDG Capital, and Bayland Capital, bring with them deep investment expertise and robust local networks. These firms are poised to provide strategic guidance and curated investment opportunities to resident startups within the Bayer Co.Lab ecosystem. The recent anniversary celebration at Bayer Co.Lab Shanghai saw the introduction of OTR Therapeutics and Nutshell Therapeutics as new startup residents. Their research and development (R&D) focus closely aligns with Bayer’s global strategic priorities, underlining a shared dedication to innovative treatment modalities targeting high unmet medical needs.
Bayer’s longstanding presence in China, spanning over 140 years, underscores the company’s commitment to fostering innovation in the region. Through the establishment of two global R&D centers and four state-of-the-art production facilities in China, Bayer has solidified its innovation footprint. Notably, more than 80% of Bayer’s major multi-center clinical trials are carried out in China, encompassing both early and late-stage clinical development. Furthermore, Bayer has cultivated strong academic-industry partnerships, forging enduring collaborations with esteemed universities such as Tsinghua University and Peking University. These partnerships have resulted in over 100 joint research projects, facilitating the translation of cutting-edge science into novel drug development endeavors.
Bayer Co.Lab stands out as a trailblazing global network of life science incubators with a sharp focus on disruptive innovation and scientific breakthroughs. Spanning strategic locations in Berlin, Germany; Cambridge, USA; Kobe, Japan; and Shanghai, China, Bayer Co.Lab serves as a nexus for early-stage entrepreneurs to access world-class expertise, resources, and global networks without constraints. As a global enterprise with core competencies in the life science domains of health care and nutrition, Bayer is guided by its mission of “Health for all, Hunger for none.” The company’s suite of products and services is meticulously designed to support endeavors aimed at addressing the significant challenges posed by a growing and aging global population.
Key Highlights:
- Bayer Co.Lab AdVenture launched to facilitate biotech innovation in China
- Collaboration with venture capital partners to accelerate growth of startups
- Introduction of inaugural partners and resident startups at Bayer Co.Lab Shanghai
- Bayer’s enduring commitment to innovation in China demonstrated through R&D centers and academic partnerships
- Bayer Co.Lab’s global network as a catalyst for disruptive innovation and scientific advancements